Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Kyung-Bok Son. (2020) Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics. Expert Review of Pharmacoeconomics & Outcomes Research 20:5, pages 541-548.
Read now
Read now
Holly McCabe, Brian Godman, Amanj Kurdi, Katie Johnston, Sean MacBride-Stewart, Janey Lennon, Simon Hurding, Marion Bennie & Alec Morton. (2019) Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications. Expert Review of Respiratory Medicine 13:7, pages 679-689.
Read now
Read now
Axel Leporowski, Brian Godman, Amanj Kurdi, Sean MacBride-Stewart, Margaret Ryan, Simon Hurding, Renata CRM Do Nascimento, Marion Bennie & Alec Morton. (2018) Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Review of Pharmacoeconomics & Outcomes Research 18:6, pages 655-666.
Read now
Read now
R. C. R. M. do Nascimento, A. A. Guerra Jr.J. Alvares, I. C. Gomes, B. Godman, M. Bennie, A. B. Kurdi & F. A. de Acurcio. (2018) Statin use in Brazil: findings and implications. Current Medical Research and Opinion 34:10, pages 1809-1817.
Read now
Read now
L. P. Thai, J. R. Moss, B. Godman & A. I. Vitry. (2016) Cost driver analysis of statin expenditure on Australia’s Pharmaceutical Benefits Scheme. Expert Review of Pharmacoeconomics & Outcomes Research 16:3, pages 419-433.
Read now
Read now
Hye-Young Kwon, Hyungmin Kim, Brian Godman & Michael R Reich. (2015) The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 1007-1014.
Read now
Read now
Jessica Fraeyman, Guido Van Hal, Brian Godman & Philippe Beutels. (2013) The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 141-151.
Read now
Read now
Pieter Dylst, Arnold Vulto & Steven Simoens. (2013) Demand-side policies to encourage the use of generic medicines: an overview. Expert Review of Pharmacoeconomics & Outcomes Research 13:1, pages 59-72.
Read now
Read now
Anna Bucsics, Brian Godman, Thomas Burkhardt, Manuela Schmitzer & Rickard E Malmström. (2012) Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 12:6, pages 809-819.
Read now
Read now
Vanda Markovic-Pekovic, Ranko Škrbić, Brian Godman & Lars L Gustafsson. (2012) Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 661-671.
Read now
Read now
AG Dupont. (2012) IMPACT OF POLICY MEASURES AND GENERIC COMPETITION ON PHARMACEUTICAL EXPENDITURE IN BELGIUM. Acta Clinica Belgica 67:3, pages 151-153.
Read now
Read now
Ljiljana Sovic Brkicic, Brian Godman, Luka Voncina, Slavica Sovic & Maja Relja. (2012) Initiatives to improve prescribing efficiency for drugs to treat Parkinson’s disease in Croatia: influence and future directions. Expert Review of Pharmacoeconomics & Outcomes Research 12:3, pages 373-384.
Read now
Read now
Mohammed Abuelkhair, Shajahan Abdu, Brian Godman, Sahar Fahmy, Rickard E Malmström & Lars L Gustafsson. (2012) Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Review of Pharmacoeconomics & Outcomes Research 12:1, pages 115-124.
Read now
Read now
Luka Vončina, Tihomir Strizrep, Brian Godman, Marion Bennie, Iain Bishop, Stephen Campbell, Vera Vlahović-Palčevski & Lars L Gustafsson. (2011) Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Review of Pharmacoeconomics & Outcomes Research 11:4, pages 469-479.
Read now
Read now
Kristina Garuoliene, Brian Godman, Jolanta Gulbinovič, Björn Wettermark & Alan Haycox. (2011) European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, pages 343-349.
Read now
Read now
Brian Godman, Solveig Sakshaug, Christian Berg, Björn Wettermark & Alan Haycox. (2011) Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Review of Pharmacoeconomics & Outcomes Research 11:1, pages 121-129.
Read now
Read now
Brian Godman, William Shrank, Morten Andersen, Christian Berg, Iain Bishop, Thomas Burkhardt, Kristina Garuoliene, Harald Herholz, Roberta Joppi, Marija Kalaba, Ott Laius, Diane McGinn, Vita Samaluk, Catherine Sermet, Ulrich Schwabe, Inês Teixeira, Lesley Tilson, F Cankat Tulunay, Vera Vlahović-Palčevski, Kamila Wendykowska, Björn Wettermark, Corinne Zara & Lars L Gustafsson. (2010) Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 707-722.
Read now
Read now
Brian Godman, Anna Bucsics, Thomas Burkhardt, Manuela Schmitzer, Björn Wettermark & Peter Wieninger. (2010) Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Review of Pharmacoeconomics & Outcomes Research 10:2, pages 199-207.
Read now
Read now
Diane McGinn, Brian Godman, Julie Lonsdale, Rosalind Way, Björn Wettermark & Alan Haycox. (2010) Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Review of Pharmacoeconomics & Outcomes Research 10:1, pages 73-85.
Read now
Read now
Anna Coma, Corinne Zara, Brian Godman, Antònia Agustí, Eduardo Diogène, Björn Wettermark & Alan Haycox. (2009) Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Review of Pharmacoeconomics & Outcomes Research 9:6, pages 569-581.
Read now
Read now
Articles from other publishers (19)
Balázs Répásy, Tibor Gazsó, Diána Elmer, Dalma Pónusz-Kovács, Fanni Luca Kajos, Tímea Csákvári, Bettina Kovács & Imre Boncz. (2023) The long-term effect of generic price competition on the Hungarian statin market. BMC Health Services Research 23:1.
Crossref
Crossref
Kyung-Bok Son & Eui-Kyung Lee. (2022) Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study. Family Practice 39:5, pages 791-798.
Crossref
Crossref
Zixuan Peng, Chaohong Zhan, Xiaomeng Ma, Honghui Yao, Xu Chen, Xinping Sha & Peter C. Coyte. (2021) Did the universal zero-markup drug policy lower healthcare expenditures? Evidence from Changde, China. BMC Health Services Research 21:1.
Crossref
Crossref
Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin & Johanna C Meyer. (2021) Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research 10:12, pages 1019-1052.
Crossref
Crossref
Evelien Moorkens, Brian Godman, Isabelle Huys, Iris Hoxha, Admir Malaj, Simon Keuerleber, Silvia Stockinger, Sarah Mörtenhuber, Maria Dimitrova, Konstantin Tachkov, Luka Vončina, Vera Vlahović Palčevski, Gnosia Achniotou, Juraj Slabý, Leona Popelková, Kateřina Kohoutová, Dorthe Bartels, Ott Laius, Jaana E. Martikainen, Gisbert W. Selke, Vasileios Kourafalos, Einar Magnússon, Rannveig Einarsdóttir, Roisín Adams, Roberta Joppi, Eleonora Allocati, Arianit Jakupi, Anita Viksna, Ieva Greičiūtė-Kuprijanov, Patricia Vella Bonanno, Vincent Suttorp, Øyvind Melien, Robert Plisko, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Corinne Zara, Vanda Marković-Peković, Nataša Grubiša, Gustaf Befrits, Robert Puckett & Arnold G. Vulto. (2021) The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology 11.
Crossref
Crossref
Yujuan Liu, Xiaoqun Lv, Ning Xie, Zhonghong Fang, Weifang Ren, Yuan Gong, Yan Jin & Jun Zhang. (2020) Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012–2018). BMC Cardiovascular Disorders 20:1.
Crossref
Crossref
Kyung-Bok Son & SeungJin Bae. (2019) Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. BMJ Open 9:3, pages e026603.
Crossref
Crossref
Christina I. Kosma, Dimitra A. Lambropoulou & Triantafyllos A. Albanis. (2016) Analysis, occurrence, fate and risks of proton pump inhibitors, their metabolites and transformation products in aquatic environment: A review. Science of The Total Environment 569-570, pages 732-750.
Crossref
Crossref
Georg Heinze, Milan Hronsky, Berthold Reichardt, Christoph Baumgärtel, Marcus Müllner, Anna Bucsics & Wolfgang C. Winkelmayer. (2014) Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study. Applied Health Economics and Health Policy 13:2, pages 193-205.
Crossref
Crossref
Hye-Young Kwon, Ji-Min Hong, Brian Godman & Bong-Min Yang. (2013) Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents. Health Policy 112:3, pages 217-226.
Crossref
Crossref
Steven Simoens, Kristien De Bruyn, Jamilette Miranda, Marion Bennie, Rickard E. Malmström & Brian Godman. (2013) Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. Journal of Pharmaceutical Health Services Research 4:3, pages 173-181.
Crossref
Crossref
B. Godman, B. Wettermark, J. Miranda, M. Bennie, A. Martin & R. E. Malmström. (2013) Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. International Journal of Clinical Practice 67:9, pages 853-862.
Crossref
Crossref
Brian Godman, Marie Persson, Jamilette Miranda, Peter Skiöld, Björn Wettermark, Corrado Barbui & Lars L. Gustafsson. (2013) Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden. Applied Health Economics and Health Policy 11:4, pages 383-393.
Crossref
Crossref
Menno van Woerkom, Hans Piepenbrink, Brian GodmanJoost de Metz, Stephen Campbell, Marion Bennie, Marietta Eimers & Lars L Gustafsson. (2012) Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. Journal of Comparative Effectiveness Research 1:6, pages 527-538.
Crossref
Crossref
Edith M. Heintjes, Fernie J. A. Penning‐van Beest, Arian W. Plat, Willem Jan Meerding, Kate Webb, Miriam C. Sturkenboom & Ron M. C. Herings. (2012) Cholesterol Level Goal Attainment with Statins: Clinical Management Guideline Recommendations versus Management in Actual Clinical Practice. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:7, pages 631-641.
Crossref
Crossref
Lars L. Gustafsson, Björn Wettermark, Brian Godman, Eva Andersén-Karlsson, Ulf Bergman, Jan Hasselström, Lars-Olof Hensjö, Paul Hjemdahl, Ingrid Jägre, Margaretha Julander, Bo Ringertz, Daniel Schmidt, Susan Sjöberg, Folke Sjöqvist, Carl-Olav Stiller, Elisabeth Törnqvist, Rolf Tryselius, Sigurd Vitols & Christer von Bahr. (2011) The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic & Clinical Pharmacology & Toxicology 108:4, pages 224-233.
Crossref
Crossref
Magda Wladysiuk, Aleksander Araszkiewicz, Brian Godman, Katarzyna Szabert, Corrado Barbui & Alan Haycox. (2011) Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland. Applied Health Economics and Health Policy 9:2, pages 101-110.
Crossref
Crossref
Jakub Adamski, Brian Godman, Gabriella Ofierska-Sujkowska, Bogusława Osińska, Harald Herholz, Kamila Wendykowska, Ott Laius, Saira Jan, Catherine Sermet, Corrine Zara, Marija Kalaba, Roland Gustafsson, Kristina Garuolienè, Alan Haycox, Silvio Garattini & Lars L Gustafsson. (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research 10:1.
Crossref
Crossref
Brian Godman, William Shrank, Bjorn Wettermark, Morten Andersen, Iain Bishop, Thomas Burkhardt, Kristina Garuolienè, Marija Kalaba, Ott Laius, Roberta Joppi, Catherine Sermet, Ulrich Schwabe, Inês Teixeira, F. Cankat Tulunay, Kamila Wendykowska, Corinne Zara & Lars L Gustafsson. (2010) Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals 3:8, pages 2470-2494.
Crossref
Crossref